ArticleESMO gastrointestinal oncology2026

Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial.

K Shitara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.